FLT3-targeted CAR-T cell therapy for relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia (AML) that has not gone away or has come back after at least one round of standard therapy.
- Your leukemia cells have the FLT3 protein (either a mutation or high levels).
- You are in generally good health (able to care for yourself, with stable organ function).
- You have not had cancer treatment with CAR-T cells before.
- You are not pregnant and agree not to get pregnant for a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses your own immune cells to fight the cancer.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
This trial tests a personalized cell therapy called CD33 CAR-T for people whose acute myeloid leukemia has come back or isn't responding to standard treatments. The goal is to see if it's safe and can help eliminate leukemia cells that carry the CD33 protein.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.